Androgens and Anabolic Steroids (AAS) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Androgens and Anabolic Steroids Market Analysis

The Androgens And Anabolic Steroids Market size is estimated at USD 70.75 billion in 2024, and is expected to reach USD 118.76 billion by 2029, at a CAGR of 10.90% during the forecast period (2024-2029).

Various factors, such as the increase in the prevalence of medical conditions, the high adoption of anabolic steroids in sports and bodybuilding, and technological advancements in androgens and anabolic steroids, will lead to market growth during the forecast period.

The growing prevalence of conditions such as hypogonadism (low testosterone levels) and delayed puberty in men is driving the need for androgen replacement therapy. For instance, an article published in the International Journal of Endocrinology in February 2023 mentioned that the worldwide prevalence of male hypogonadism (MH) ranges from 6% to 12%, depending on the specific study population. Additionally, anabolic steroids are also utilized in treating conditions that lead to muscle wasting, including cancer and other various chronic diseases. For instance, according to the data updated by the Global Observatory Council (GLOBOCON) in February 2024, reported that the incidence of breast cancer is expected to rise from 2.3 million cases in 2022 to 2.7 million in 2030. Thus, the increasing number of breast cancer patients are anticipated to utilize anabolic steroids for the treatment of estrogen receptor-positive breast cancer with the reduction of estrogen levels, which, in turn, is expected to boost market growth.

Additionally, market players incorporate strategies to introduce technologically advanced drug delivery systems, including long-acting injectables and topical treatments, which have simplified androgen therapies for patients, driving the market growth. For instance, in November 2023, Astellas Pharma Inc. entered into an agreement to acquire Propella Therapeutics, Inc. Through this acquisition, Astellas gained access to PRL-02 (abiraterone decanoate), an advanced androgen biosynthesis inhibitor under development by Propella for prostate cancer treatment. PRL-02 is an innovative, long-acting prodrug of abiraterone, which may offer enhanced efficacy and safety compared to current treatment alternatives due to its high selectivity in inhibiting CYP17 lyase. Moreover, according to the data published by the Hair Science Organization in June 2023, mentioned that GT20029 is an innovative topical androgen receptor degrader medication developed by Kintor Pharmaceutical Ltd. to address pattern hair loss (androgenetic alopecia) and acne vulgaris. The drug has successfully completed phase I clinical trials involving both men and women in China and the United States, and phase II clinical trials have started. Thus, such market player initiatives to introduce innovative products are anticipated to drive their usage, thereby boosting the market growth.

Hence, the increase in the prevalence of medical conditions such as hypogonadism and breast cancer among patients and market player strategies to introduce technologically advanced androgen and anabolic steroids are the significant factors driving the market growth. However, the regulatory and legal restrictions, as well as side effects and health risks, may affect the market growth of androgens and anabolic steroids over the forecast period.

Androgens and Anabolic Steroids Market Trends

Testosterone Segment is Witnessed to Hold the Largest Share Over the Forecast Period

Androgens and Anabolic Steroids Industry Segmentation

According to the scope, androgens are natural hormones crucial for male development and reproduction. In contrast, anabolic steroids are synthetic substances developed to replicate these effects, primarily focusing on muscle growth and tissue repair. These steroids are utilized to address delayed puberty in adolescent males, breast cancer in females, and conditions like hypogonadism and impotence in males. Additionally, they treat anemia, osteoporosis, weight loss, and various other disorders related to hormonal imbalances.

The androgens and anabolic steroids market is segmented by product type, application, route of administration, end-user, distribution channel, and geography. By product type, the market is segmented into testosterone, methyltestosterone, oxandrolone, and other anabolic steroids. By application, the market is segmented into hypogonadism, anemia, breast cancer, and other applications. By route of administration, the market is segmented into oral, injectable, and other routes of administration. By end-user, the market is segmented into hospitals, specialty clinics, homecare settings and other end users. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.